首页> 外文期刊>Infection and immunity >Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.
【24h】

Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.

机译:源自铜绿假单胞菌的七价高分子量O-多糖疫苗的免疫原性和抗原性。

获取原文
           

摘要

We investigated the chemical and immunologic properties of a heptavalent vaccine composed of high-molecular-weight polymers of the lipopolysaccharide (LPS) O polysaccharides representative of the most common clinical isolates of Pseudomonas aeruginosa. We also evaluated the serum antibody response to nonvaccine strains of P. aeruginosa, including strains expressing structural variants (subtype strains) of the O side chain of the vaccine strains. The polyvalent vaccine, prepared under conditions suitable for human use, contained low levels of contaminants and passed preclinical safety and toxicity tests required for human use. Chemical analyses indicated that individual polysaccharides were composed of both O-side chain and core sugars. Following immunization of C3H/HeN mice and New Zealand White rabbits, antibody titers against vaccine components increased between 32- and 200-fold. Antibodies reactive with LPS isolated from smooth and rough nonvaccine strains were also elicited. Analysis of the opsonic activity against the known LPS subtype variants of the vaccine strains revealed a variable pattern of killing, which ranged from opsonic killing of > or = 69% of bacterial cells representing all subtype variants within a serogroup to opsonization of only a minority of the subtype variant strains. Mouse and rabbit immune sera showed different patterns of opsonic activity against subtype strains, indicating that different epitopes on these antigens are immunodominant in the representatives of these two animal species tested. The polyvalent vaccine was effective at eliciting antibodies to vaccine components in mice and rabbits, but it remains to be determined if the current heptavalent formulation contains sufficient components to provoke human antibodies reactive with a majority of clinical strains of P. aeruginosa.
机译:我们调查了由代表多糖铜绿假单胞菌最常见临床分离株的脂多糖(LPS)O多糖的高分子量聚合物组成的七价疫苗的化学和免疫学性质。我们还评估了对铜绿假单胞菌的非疫苗菌株的血清抗体反应,包括表达疫苗菌株O侧链结构变异体(亚型菌株)的菌株。在适合人类使用的条件下制备的多价疫苗含有低含量的污染物,并通过了人类使用所需的临床前安全性和毒性测试。化学分析表明,各个多糖均由O侧链糖和核心糖组成。在对C3H / HeN小鼠和新西兰白兔免疫后,针对疫苗成分的抗体效价提高了32到200倍。还引发了与从光滑和粗糙的非疫苗株中分离出的与LPS反应的抗体。针对疫苗株的已知LPS亚型变体的调理活性分析显示了不同的杀伤模式,其范围包括对代表血清群中所有亚型变体的细菌细胞进行>或= 69%的调理杀伤,或者仅对少量的调理素进行调理作用。亚型变异株。小鼠和兔子的免疫血清对亚型毒株表现出不同的调理活性模式,表明在这两种受测动物的代表中,这些抗原上的不同表位具有免疫优势。该多价疫苗可有效引发小鼠和兔子中疫苗成分的抗体,但目前的七价制剂是否包含足以引起与大多数铜绿假单胞菌临床菌株反应的人抗体的成分,仍有待确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号